195 related articles for article (PubMed ID: 35358872)
1. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
[TBL] [Abstract][Full Text] [Related]
2. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
3. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
[TBL] [Abstract][Full Text] [Related]
4. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
5. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
7. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.
Nemoto S; Nakamura M; Osawa Y; Kono S; Itoh Y; Okano Y; Murate T; Hara A; Ueda H; Nozawa Y; Banno Y
J Biol Chem; 2009 Apr; 284(16):10422-32. PubMed ID: 19240026
[TBL] [Abstract][Full Text] [Related]
11. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
Tanaka S; Hosokawa M; Yonezawa T; Hayashi W; Ueda K; Iwakawa S
Biol Pharm Bull; 2015; 38(3):435-40. PubMed ID: 25757925
[TBL] [Abstract][Full Text] [Related]
12. [Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells].
Zhang Y; Sun XW; Xu JH; Lu H; Fan ZZ; Sun J; Zhang XX
Zhong Xi Yi Jie He Xue Bao; 2012 Aug; 10(8):901-10. PubMed ID: 22883407
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling.
Iuchi K; Tasaki Y; Shirai S; Hisatomi H
Biomed Pharmacother; 2020 May; 125():109928. PubMed ID: 32004978
[TBL] [Abstract][Full Text] [Related]
14. In vitro exosomal transfer of Nrf2 led to the oxaliplatin resistance in human colorectal cancer LS174T cells.
Mostafazadeh M; Kahroba H; Haiaty S; TazeKand AP; Samadi N; Rahbarghazi R; Nouri M
Cell Biochem Funct; 2022 Jun; 40(4):391-402. PubMed ID: 35474580
[TBL] [Abstract][Full Text] [Related]
15. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.
Eades G; Yang M; Yao Y; Zhang Y; Zhou Q
J Biol Chem; 2011 Nov; 286(47):40725-33. PubMed ID: 21926171
[TBL] [Abstract][Full Text] [Related]
16. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy.
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Oncol Rep; 2016 Dec; 36(6):3682-3690. PubMed ID: 27779719
[TBL] [Abstract][Full Text] [Related]
18. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
[TBL] [Abstract][Full Text] [Related]
19. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity.
Wang Z; Zhang L; Ni Z; Sun J; Gao H; Cheng Z; Xu J; Yin P
Tumour Biol; 2015 Dec; 36(12):9499-510. PubMed ID: 26124005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
